Jinekolojik Kanserlerden Korunma
Özet
Jinekolojik kanserler, mortalite ve morbidite açısından dünyada ve ülkemizde kadın sağlığını tehdit eden önemli sağlık sorunları arasında ilk on sırada yer almaktadır. Sağlık sistemlerine büyük ekonomik ve fiziki yük getiren bu kanser türlerinin kontrol altına alınması amacıyla literatürde birincil, ikincil ve üçüncül olmak üzere üç korunma basamağı uygulanmaktadır. Birincil korunma; serviks, over, endometrium, vulva ve vajina gibi kanser türleri oluşmadan önce riskli davranışlardan uzak durmayı, sağlıklı yaşam tarzı geliştirmeyi ve özellikle HPV ilişkili jinekolojik kanserler için hayati önem taşıyan HPV aşılamasını içerir. İkincil korunma, asemptomatik dönemdeki kadınların erken teşhisini hedefler; serviks kanserinde Pap smear ve HPV-DNA testleri yaygın tarama yöntemi olarak kullanılırken, over ve endometrium gibi kanserlerde spesifik bir tarama testi olmaması nedeniyle genetik danışmanlık, riskli grupların takibi ve semptomların izlenmesi ön plana çıkar. Üçüncül korunma ise teşhis sonrası uygun tedavi yönetimini, cerrahi, kemoterapi, radyoterapi gibi multidisipliner yaklaşımları ve hastaların yaşam kalitesini artıracak palyatif bakım ile rehabilitasyon hizmetlerini kapsamaktadır. Sonuç olarak, kadın sağlığını derinden etkileyen bu hastalıkların yükünü azaltmak için jinekolojik kanser korunma hizmetlerinin her kademede sürekli, erişilebilir ve sürdürülebilir kılınması gerekmektedir.
Gynecological cancers rank among the top ten significant health problems threatening women's health worldwide and in Turkey in terms of mortality and morbidity. In order to control these types of cancers, which impose a major economic and physical burden on health systems, three levels of prevention—primary, secondary, and tertiary—are implemented in the literature. Primary prevention includes staying away from risky behaviors, developing a healthy lifestyle before cancers such as cervix, ovary, endometrium, vulva, and vagina develop, and HPV vaccination, which is vital for HPV-related gynecological cancers. Secondary prevention aims at the early diagnosis of asymptomatic women; while Pap smear and HPV-DNA tests are used as common screening methods in cervical cancer, due to the lack of a specific screening test in cancers such as ovarian and endometrial, genetic counseling, monitoring of risky groups, and symptom surveillance come to the fore. Tertiary prevention encompasses appropriate treatment management after diagnosis, multidisciplinary approaches such as surgery, chemotherapy, and radiotherapy, and palliative care and rehabilitation services that will improve the quality of life of patients. Consequently, to reduce the burden of these diseases deeply affecting women's health, gynecological cancer prevention services must be made continuous, accessible, and sustainable at every stage.
Referanslar
Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca Cancer J Clın, 2021;0:1–41.
Türkiye Kanser İstatistikleri 2016. Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü, 2018 (20.04.2021 tarihinde https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri/yillar/2016-yili-turkiye-kanser-i-statistikleri.html adresinden ulaşılmıştır).
American Cancer Society Cancer Facts & Figures (2021) (20.04.2021 tarihinde https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html adresinden ulaşılmıştır).
Wild CP, Weiderpass E, Stewart BW. World Cancer Report Cancer Research for Cancer Prevention. WHO-IARC, 2020.
Global Cancer Program Strategy 2020-2025 (20.04.2021 tarihinde https://www.uhn.ca/PrincessMargaret/Global_Cancer_Program/Documents/GO_Strategy_Document.pdf adresinden ulaşılmıştır).
Eroğlu K, Koç G. Jinekolojik Kanser Kontrolü ve Hemşirelik. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi, 2014; 77–90.
National Cancer Control Programmes (NCCP) (20.04.2021 tarihinde https://www.who.int/cancer/nccp/en/ adresinden ulaşılmıştır).
World Health Organization (2017) Guide to Cancer Early Diagnosis ISBN 978-92-4-151194-0 (20.04.2021 tarihinde https://www.who.int/cancer/publications/cancer_early_diagnosis/en/ adresinden ulaşılmıştır).
Özerdoğan N,Gürsoy E. Serviks Kanserinde Korunma ve Hemşirelik. Türkiye Klinikleri J Obstet Womens Health Dis Nurs-Special Topics, 2017;3(1).
Global strategy towards eliminating cervical cancer as a public health problem. WHO 2020.
Straughn JM, Yashar C. Management of early-stage cervical cancer. Up to date. 2021.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. Lyon (FR): International Agency for Research on Cancer; 2007. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 90.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK321760/ Access date: 15.10.2021
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 157. Cervical Cancer Screening and Prevention. Obstet Gynecol , 2016; 127 (1).
Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C. Therapeutic Vaccines for HPV-Associated Malignancies. Immunotargets Ther. 2020 Oct 7;9:167-200.
Fontham E, Wolf A, Church T et al. Servical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update from the American Cancer Society. Ca Cancer J Clın, 2020;70:321–346
T.C Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü Kanser Dairesi Başkanlığı Serviks Kanseri Tarama Programı Ulusal Standartları (20.04.2021 tarihinde https://hsgm.saglik.gov.tr/tr/kanser-tarama-standartlari/listesi/serviks-kanseri-tarama-program%C4%B1-ulusal-standartlar%C4%B1.html adresinden ulaşılmıştır).
Demirel G, Gölbaşı Z. Kadın sağlığı taramasında güncel durum. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi, 2015;4(4).638-59.
Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019; 35(2):151-156.
Foong KW, Bolton H. Obesity and ovarian cancer risk: A systematic review. Post Reprod Health. 2017; 23(4): 183-198.
Chen L, Berek J. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum:epidemiology and risk factors. Up to Date 2012
Wentzensen N, Poole EM, Trabert B et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol. 2016; 34(24):2888–98.
Babic A, Sasamoto N, Rosner BA, et al. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncol. 2020; 6(6): e200421.
Modugno F, Goughnour SL, Wallack D, et al. Breastfeeding factors and risk of epithelial ovarian cancer. Gynecol Oncol. 2019; 153(1): 116-122.
Chen LM, Berek J. Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum. Up to date. 2021.
Kalaitzopoulos DR, Mitsopoulou A, Rafail D, et al. Association between endometriosis and gynecological cancers: a critical review of the literature . Archives of Gynecology and Obstetrics, 2020; 301:355–367.
Schmid D, Behrens G, Keimling M, et al.A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol, 2015;30:397-412.
Passarello K, Kurian S, Villanueva V. Endometrial Cancer: An Overview of Pathophysiology, Management, and Care. Semin Oncol Nurs. 2019; 35(2): 157-165.
Njoku K, Abiola J, Russell J, Crosbie EJ. Endometrial cancer prevention in high-risk women. Best Pract Res Clin Obstet Gynaecol. 2020; 65: 66-78.
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J of Gynecol Cancer, 2016; 27(1); 2-30. https://www.esgo.org/media/2015/12/endometriyum-tr.pdf
Rogers LJ, Cuello MA. Cancer of the vulva. Int J Gynaecol Obstet. 2018; 143 Suppl 2: 4-13.
Keskin HG, Tahta T. Vulva kanseri ve vulvektomi sonrası hemşirelik yaklaşımları. Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi, 2021: 5(1); 115-121.
Chen Y, Bruning E, Rubino J, Eder SE. Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. Womens Health (Lond). 2017; 13(3):58-67.
Tan A, Bieber AK, Stein JA, Pomeranz MK. Diagnosis and management of vulvar cancer: A review. J Am Acad Dermatol. 2019; 81(6): 1387-1396.
Pérez-López FR, Vieira-Baptista P. Lichen sclerosus in women: a review. Climacteric. 2017; 20(4): 339-347.
Singh N, Negi N, Srivastava K, Agarwal G. A cohort study of vulvar cancer over a period of 10 years and review of literature. Indian J Cancer. 2016; 53(3): 412-415.
Satmary W, Holschneider CH, Brunette LL, Natarajan S. Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol. 2018; 148(1): 126-131.
Adams TS, Cuello MA. Cancer of the vagina. Int J Gynaecol Obstet. 2018; 143 Suppl 2: 14-21.
Karam MD, Berek JS, Kidd EA. Vaginal cancer. UpToDate, 2021.
Lamos C, Mihaljevic C, Aulmann S, et al. Detection of Human Papillomavirus Infection in Patients with Vaginal Intraepithelial Neoplasia. PLoS One. 2016; 11(12): e0167386.
Madore WJ, De Montigny E, Deschênes A, et al. Morphologic three-dimensional scanning of fallopian tubes to assist ovarian cancer diagnosis. J Biomed Opt. 2017; 22(7): 76012.
Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT. Role of Fallopian Tubes in the Development of Ovarian Cancer. J Minim Invasive Gynecol. 2017 Feb;24(2):230-234.
